Policy | February 01, 2026
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Subscribe To Our Newsletter & Stay Updated
